Abstract
Cyclosporin A (CsA) has been used most widely as an immunosuppressive agent for preventing graft-versus-host disease (GVHD). To explore the risk factors including CsA blood levels for grades II–IV acute GVHD, we retrospectively analyzed the data of patients who underwent allogeneic hematopoietic stem cell transplantation in our hospital between March 1989 and July 2001. Seventy-three patients (47 males and 26 females) received CsA and short-term methotrexate for GVHD prophylaxis. CsA 1.5 mg/kg was administered as a 3-h infusion twice daily from day 1 until the patient recovered from the toxic gastrointestinal complication. Methotrexate was given at a dose of 15 mg/m2 on day 1 and 10 mg/m2 on days 3, 6 and 11. Grades II–IV acute GVHD occurred in 18 patients (24.7%). Multivariate Cox regression analysis revealed that higher C5 (the whole-blood CsA concentration at 5 h after the start of infusion) before the onset of acute GVHD reduced the onset of grades II–IV acute GVHD with a hazard ratio of 0.994 (95% confidence interval 0.989–0.999) for every increase of 1 ng/ml. Our data indicate that inadequate exposures of CsA can be a vital risk for developing acute GVHD. From our results, we consider that precise monitoring of CsA concentrations and adjustment of CsA dose using the concentration may be effective to prevent the onset of severe acute GVHD. To confirm this finding, further prospective study will be needed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Devergie A . Graft vs. host disease. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T (eds). Haemopoietic Stem Cell Transplantation. European School of Hematology: Paris, 2004, pp 163–176.
Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, Deeg HJ . Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med 1988; 319: 65–70.
Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838–1845.
Martin P, Bleyzac N, Souillet G, Galambrun C, Bertrand Y, Maire PH et al. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003; 32: 777–784.
Martin P, Bleyzac N, Souillet G, Galambrun C, Bertrand Y, Maire PH et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003; 32: 881–887.
Ogawa N, Kanda Y, Matsubara M, Asano Y, Nakagawa M, Sakata-Yanagimoto M et al. Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion. Bone Marrow Transplant 2004; 33: 549–552.
Sato N, Furukawa T, Kuroha T, Hashimoto S, Masuko M, Takahashi H et al. High-dose cytosine arabinoside and etoposide with total body irradiation as a preparatory regimen for allogeneic hematopoietic stem-cell transplantation in patients with acute lymphoblastic leukemia. Bone Marrow Transplant 2004; 34: 299–303.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.
Schran HF, Rosano TG, Hassell AE, Pell MA . Determination of cyclosporine concentrations with monoclonal antibodies. Clin Chem 1987; 33: 2225–2229.
Lindholm A, Napoli K, Rutzky L, Kahan BD . Specific monoclonal radioimmunoassay and fluorescence polarization immunoassay for trough concentration and area-under-the-curve monitoring of cyclosporine in renal transplantation. Ther Drug Monit 1992; 14: 292–300.
Halloran P . Calcineurin inhibition-relationship to cyclosporine blood concentration. Focus Med 1998; 13: 15–18.
Kahan BD . Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc 2004; 36: 378S–391S.
Nashan B, Cole E, Levy G, Thervet E . Clinical validation studies of Neoral C(2) monitoring: a review. Transplantation 2002; 73: S3–S11.
Levy G, Thervet E, Lake J, Uchida K, Consensus on Neoral C(2): Expert Review in Transplantation (CONCERT) Group. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation 2002; 73: S12–S18.
Duncan N, Craddock C . Optimizing the use of cyclosporin in allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38: 169–174.
Ruutu T, Niederwieser D, Gratwohl A, Apperley JF . A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic leukaemia working party of the EBMT. Bone Marrow Transplant 1997; 19: 759–764.
Acknowledgements
We thank Miyako Baba and Yoko Tanahashi, Clinical Laboratory Division, Niigata University Medical and Dental Hospital for their excellent technical assistance and helpful discussion.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Izumi, N., Furukawa, T., Sato, N. et al. Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A. Bone Marrow Transplant 40, 875–880 (2007). https://doi.org/10.1038/sj.bmt.1705834
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705834
Keywords
This article is cited by
-
Prophylactic and therapeutic treatment of graft-versus-host disease in Japan
International Journal of Hematology (2015)
-
Risk Factors, Pattern and Clinical Outcome of Acute Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplant
Indian Journal of Hematology and Blood Transfusion (2015)
-
Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single time point for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantation
International Journal of Hematology (2010)
-
Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients
Bone Marrow Transplantation (2008)